US00287Y1091 - ABBV - A1J84E (XNYS)
ABBVIE INC Aktie
193,47 USD
Aktuelle Kurse von ABBVIE INC
Börse | Ticker | Währung | Letzter Umsatz | Kurs | Tagesveränderung | Tagesveränderung % |
---|---|---|---|---|---|---|
NYSE |
ABBV
|
USD
|
21.09.2024 00:28
|
193,47 USD
| 193,63 USD | -0,08 % |
XETRA |
4AB.DE
|
EUR
|
20.09.2024 17:35
|
173,28 EUR
| 173,16 EUR | 0,07 % |
Performance
Tag | Woche | Monat | 3 Monate | 6 Monate | 1 Jahr | 5 Jahre |
---|---|---|---|---|---|---|
-0,08 % | -0,38 % | -1,44 % | 14,44 % | 8,74 % | 25,77 % | 116,93 % |
Firmenprofil zu ABBVIE INC Aktie
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Investierte Fonds
Folgende Fonds haben in ABBVIE INC investiert:
Fonds | Vol. in Mio 9.198,56 | Anteil (%) 2,52 % |
Fonds | Vol. in Mio 2.322,89 | Anteil (%) 1,89 % |
Fonds | Vol. in Mio 801,98 | Anteil (%) 1,68 % |
Fonds | Vol. in Mio 3.006,31 | Anteil (%) 1,16 % |
Fonds | Vol. in Mio 12.810,58 | Anteil (%) 1,06 % |
Unternehmensdaten zur ABBVIE INC Aktie
Name ABBVIE INC
Firma AbbVie Inc.
Symbol ABBV
Website https://www.abbvie.com
Heimatbörse
NYSE
WKN A1J84E
ISIN US00287Y1091
Wertpapierart Aktie
Sektor Healthcare
Branche Drug Manufacturers - General
CEO Mr. Robert A. Michael
Marktkapitalisierung 342 Mrd.
Land Vereinigte Staaten von Amerika
Währung USD
Mitarbeiter 50,0 T
Adresse 1 North Waukegan Road, 60064-6400 North Chicago
IPO Datum 2013-01-02
Dividenden von ABBVIE INC
Ex-Datum | Dividende pro Aktie |
---|---|
15.07.2024 | 1,55 USD |
12.04.2024 | 1,55 USD |
12.01.2024 | 1,55 USD |
12.10.2023 | 1,48 USD |
13.07.2023 | 1,48 USD |
13.04.2023 | 1,48 USD |
12.01.2023 | 1,48 USD |
13.10.2022 | 1,41 USD |
14.07.2022 | 1,41 USD |
13.04.2022 | 1,41 USD |
Ticker Symbole
Name | Symbol |
---|---|
Frankfurt | 4AB.F |
NYSE | ABBV |
XETRA | 4AB.DE |
Weitere Aktien
Investoren die ABBVIE INC halten haben auch folgende Aktien im Depot:
Die Finanzplattform goSPATZ trackt und analysiert Investitionen und Portfolios.
Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
All rights reserved © LCP GmbH 2024